NGS Sample Preparation Market
Number of pages: 100 | Report Format: PDF | Published date: March 22, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.46 billion |
|
Revenue Forecast in 2031 |
US$ 4.22 billion |
|
CAGR |
12.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product & Services, Workflow, Sample Type, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global NGS sample preparation market was valued at US$ 1.46 billion in 2022 and is expected to register a revenue CAGR of 12.5% to reach US$ 4.22 billion by 2031.
NGS Sample Preparation Market Fundamentals
Next-generation sequencing (NGS) is a massively parallel sequencing technology that provides ultra-high throughput, scalability, and speed. The method is used to identify the nucleotide order of whole genomes or specific portions of DNA or RNA. NGS has transformed the biological sciences, allowing labs to undertake a wide range of applications and analyses of biological systems to a previously unimaginable degree. However, all NGS platforms can parallel sequence millions of tiny DNA fragments. By mapping individual reads to the human reference genome, bioinformatics methods are employed to put together these fragments. Each of the human genome’s three billion bases is sequenced numerous times, giving tremendous depth to offer precise data and insight into unexpected Genetic variation. NGS may be used to sequence complete genomes or specific sections of interest, such as all 22 000 coding genes (a full exome) or a limited number of individual genes.
NGS, also known as deep sequencing, is a method that allows for huge parallel multiplexed analysis of DNA sequences—millions to billions of sequences from every single strand of DNA studied independently, yet simultaneously. This technique allows for the comprehensive examination of a human genome in a matter of days for a few thousand dollars. Without a certain, as technology progresses, the pace and cost will reduce to the point where receiving entire sequence analysis of malignancies and matched germline for each patient will be feasible. The biggest restriction is the need for enhanced information technology to collect the huge amounts of data generated by these analyzers, filter the data into valuable medical information, and store it for future use.
With the introduction of NGS technology, high-throughput identification of numerous genetic changes in constitutional and cancer genomes has become possible. NGS allows for the vast, parallel sequencing of hundreds to millions of small nucleic acid sequences. It outperforms traditional sequencing techniques, such as Sanger sequencing, by sequencing huge genome sections cheaper and with improved sensitivity. NGS may be conducted at several degrees of complexity, including whole genome sequencing, whole exome sequencing, whole transcriptome sequencing (mRNA sequencing), and multigene panel targeted sequencing. While large-scale studies are necessary for discovery initiatives, focused panels are more likely to deliver additional advancements in routine molecular diagnostics of numerous illnesses, including cancer.
Cancer is a disease of the genome, according to the core assumption of cancer genomics. Somatically acquired mutations cause cancer. Although capillary-based cancer sequencing has been ongoing for over a decade, these studies have been confined to several samples and candidate genes. Cancer genomes may now be systematically explored in their entirety owing to the introduction of NGS. This endeavor is underway through multiple large-scale cancer genome initiatives worldwide, including a specialized pediatric cancer genome study.
[78568]
NGS Sample Preparation Market Dynamics
The primary factors driving market expansion are the increased cases of infectious diseases, lower sequencing costs, and technological advancements in NGS platforms. With the increasing prevalence of infectious diseases, NGS sequencing technologies have quickly become the method of choice in virology for a wide range of applications, including the detection of novel viruses from metagenomic samples, the reconstruction of whole or nearly complete viral genome sequences, and the analysis of viral evolution and subspecies. For instance, according to the WHO August 2022 Influenza Report, from 11 July 2022 to 24 July 2022, National Influenza Centers and other national influenza labs from 120 countries, regions, or territories contributed data to FluNet. The WHO Global Influenza Surveillance and Response System laboratories analyzed over 145,086 samples during that period. About 97.7% of the 6,449 persons who tested positive for influenza viruses had influenza A, whereas 2.3% had influenza B.
The diagnostic phase is expected to expand significantly throughout the projection period. Genome sequencing of male and female cancer patients has been supplemented using NGS basic genomic sequencing, which has become quicker and significantly less expensive each year. This has enabled NGS to be used not just in research but also in scientific practice. In August 2020, the European Society for Medical Oncology (ESMO) proposed three sets of recommendations for NGS. ESMO encourages the widespread usage of NGS on tumor tissues to treat non-small cell, non-squamous upper lung cancer, cholangiocarcinoma, ovarian malignancies, and prostate cancers. NGS may eventually replace PCR in the diagnosis of colon cancer. NGS may be useful for identifying multiple genes and their modifications simultaneously by sequencing hundreds of thousands of DNA reads and using healing decision-making.
NGS Sample Preparation Market Ecosystem
The global NGS sample preparation market has been analyzed from five perspectives: product & services, workflow, sample type, application, end-user, and region.
NGS Sample Preparation Market by Product & Services
[85766]
Based on products & services, the global NGS sample preparation market has been segmented into instruments, reagents & consumables, and services.
The instruments segment accounted for the largest revenue share of the global NGS sample preparation market. Technological improvements, more product approvals and launches, partnerships, and collaborations among major companies drive growth in the diagnostics industry. For instance, in February 2021, QIAGEN and INOVIO expanded their collaboration to develop a companion diagnostic for INOVIO’s VGX-3100 for advanced cervical dysplasia utilizing NGS. Additionally, Guardant Health Inc. gained FDA clearance for Guardant360 CDx in August 2020, which employs two combination technologies, liquid biopsy and NGS, in a single diagnostic test. As a result, the increased product approval for NGS diagnostics and product launches may open up new potential for the segment.
NGS Sample Preparation Market by Workflow
Based on workflow, the global NGS sample preparation market has been segmented into DNA fragmentation & library preparation, target enhancement, and quality control.
The DNA fragmentation & library preparation segment is expected to account for the largest revenue share during the forecast period. The rising prevalence of genetic diseases across the globe is projected to drive revenue growth in the library preparation segment in the coming years. According to the WHO, one in every 1000 newborns is affected by a single gene disorder. NGS is mostly used for diagnosis in the treatment of genetic diseases. As a result, this is a significant market driver for the usability of NGS and, by extension, library preparation. For instance, Genes2Me was expected to launch a wide range of NGS panels for cancer and genetic illnesses in May 2022, utilizing platforms such as Illumina, Thermo Fisher ION, and others.
NGS Sample Preparation Market by Sample Type
Based on sample type, the global NGS sample preparation market has been segmented into DNA and RNA.
The DNA segment captures the largest revenue share in the global NGS sample preparation market. NGS detects a greater range of mutations than Sanger sequencing. Tiny base alterations (substitutions), insertions and deletions of DNA, major genomic deletions of exons or whole genes, and rearrangements, such as inversions and translocations, compose the spectrum of DNA variation in the human genome.
NGS Sample Preparation Market by Application
Based on application, the global NGS sample preparation market has been segmented into disease diagnostics, drug diagnostics, agriculture & animal research, and others. The disease diagnostics segment is further sub-segmented into cancer, reproductive health, and infectious disease diagnostics.
The disease diagnostics segment will likely dominate the market during the forecast period. NGS reads all genes relevant to a specific phenotype to discover the causal contribution to a disease state. Moreover, NGS allows for the simultaneous examination of several genes, possibly saving time, money, and tissue if many possible indicators need to be tested for the disease. Illumina Inc., for instance, declares the release of a novel NGS-based diagnostic test for identifying genito-urinary pathogens and antimicrobial resistance using precision metagenomics to detect and quantify over 170 pathogens and more than 3700 markers associated with 18 different drug classes in November 2022.
NGS Sample Preparation Market by End User
Based on end user, the global NGS sample preparation market has been segmented into hospitals & clinics, academic institutes & research centers, pharmaceuticals & biotechnology companies, and others.
The academic institutes & research centers segment is projected to account for the highest revenue share during the forecast period. To improve the results of biological and biomedical research, NGS-based high-throughput sequencing technologies have been widely used in specialized research activities, such as gene expression profiling, chromatin immunoprecipitation, and small-RNA sequencing. In March 2021, for instance, researchers at the University of California signed a collaboration agreement with Miroculus, Inc. and Purigen Biosystems to develop a revolutionary tool for personal lab automation to optimize an automated PCR-free whole genome sequencing library preparation workflow with micro-input human samples.
NGS Sample Preparation Market by Region
Based on region, the global NGS sample preparation market has been segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa.
North America accounts for the highest market revenue share among other regional markets in the NGS sample preparation market. It is expected to maintain this position throughout the forecast period. Rapid breakthroughs in NGS, acceptance of personalized medicine, increase in investments in research and development by major corporations, and the domination of key market participants in this region all contribute to the high revenue contribution.
North America is expected to have significant market expansion opportunities due to the increasing demand for diagnostic tools for identifying health inequalities and the region’s expanding burden of infectious and chronic illnesses. The rising focus of top market players on technological innovation, product launches, collaborations, and acquisitions is driving market expansion in North America. For instance, Illumina Inc. and Nashville Biosciences LLC, a Vanderbilt University Medical Center subsidiary, signed a multi-year agreement in January 2022 to accelerate medicine development through large-scale genomics and the establishment of a clinical-genomic resource using Illumina’s NGS platforms. Such activities are projected to promote the revenue growth of the North American NGS sample preparation market.
Key product launches, a high concentration of market players or manufacturers’ presence, acquisitions and partnerships among major players, and increased funding from the federal government and private players are some of the factors driving revenue growth of the NGS sample preparation market in the United States. For instance, Agilent Technologies purchased Resolution Bioscience, a pioneer in the research and marketing of NGS-based precision cancer products, in April 2021. Similarly, in January 2020, the Intelligence Advanced Research Projects Activity in the United States provided US$ 23.0 million to the Broad Institute, Harvard University, and DNA Script. The organizations have been investigating the prospect of merging enzymatic DNA synthesis technology with NGS into a single device for more than four years. Thus, such encouraging trends are expected to drive revenue growth in the United States market throughout the forecast period.
The Asia Pacific region will likely develop significantly due to the increased cases of rare illnesses and high population density. Furthermore, leading industry participants are preparing to penetrate the Asia Pacific market with their NGS library preparation skills. For instance, in May 2021, BGI inked a deal with Ethiopian Biotechnology Institute to conduct pilot-scale HPV genotyping testing to develop a novel approach for HPV screening, diagnosis, and therapy.
NGS Sample Preparation Market Competitive Landscape
The prominent players in the global NGS sample preparation market include:
NGS Sample Preparation Market Strategic Developments
Asia Pacific is the key growth region in the global NGS sample preparation market.
The NGS sample preparation market is expected to reach 4.22 billion by 2031.
The NGS sample preparation market is expected to register a revenue CAGR of 12.5% during the forecast period.
The prominent market players in the global NGS sample preparation market include Illumina, Inc., Agilent Technologies, Inc., and Thermo Fisher Scientific, Inc.
The disease diagnostics segment dominates the global NGS sample preparation market.
*Insights on financial performance are subject to the availability of information in the public domain